Publication:

Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma

Date

Date

Date
2022
Journal Article
Published version

Citations

Citation copied

Bhave, P., Ahmed, T., Lo, S. N., Shoushtari, A., Zaremba, A., Versluis, J. M., Mangana, J., Weichenthal, M., Si, L., Lesimple, T., Robert, C., Trojanello, C., Wicky, A., Heywood, R., Tran, L., Batty, K., Dimitriou, F., Stansfeld, A., Allayous, C., … et al. (2022). Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma. Journal for ImmunoTherapy of Cancer, 10, e004668. https://doi.org/10.1136/jitc-2022-004668

Abstract

Abstract

Abstract

BackgroundAcral melanoma is a rare melanoma subtype with poor prognosis. Importantly, these patients were not identified as a specific subgroup in the landmark melanoma trials involving ipilimumab and the anti-programmed cell death protein-1 (PD-1) agents nivolumab and pembrolizumab. There is therefore an absence of prospective clinical trial evidence regarding the efficacy of checkpoint inhibitors (CPIs) in this population. Acral melanoma has lower tumor mutation burden (TMB) than other cutaneous sites, and primary site is associated

Additional indexing

Creators (Authors)

  • Bhave, Prachi
    affiliation.icon.alt
  • Ahmed, Tasnia
    affiliation.icon.alt
  • Lo, Serigne N
    affiliation.icon.alt
  • Shoushtari, Alexander
    affiliation.icon.alt
  • Zaremba, Anne
    affiliation.icon.alt
  • Versluis, Judith M
    affiliation.icon.alt
  • Mangana, Joanna
    affiliation.icon.alt
  • Weichenthal, Michael
    affiliation.icon.alt
  • Si, Lu
    affiliation.icon.alt
  • Lesimple, Thierry
    affiliation.icon.alt
  • Robert, Caroline
    affiliation.icon.alt
  • Trojanello, Claudia
    affiliation.icon.alt
  • Wicky, Alexandre
    affiliation.icon.alt
  • Heywood, Richard
    affiliation.icon.alt
  • Tran, Lena
    affiliation.icon.alt
  • Batty, Kathleen
    affiliation.icon.alt
  • Dimitriou, Florentia
    affiliation.icon.alt
  • Stansfeld, Anna
    affiliation.icon.alt
  • Allayous, Clara
    affiliation.icon.alt
  • Schwarze, Julia K
    affiliation.icon.alt
  • Mooradian, Meghan J
    affiliation.icon.alt
  • Klein, Oliver
    affiliation.icon.alt
  • Mehmi, Inderjit
    affiliation.icon.alt
  • Roberts-Thomson, Rachel
    affiliation.icon.alt
  • Maurichi, Andrea
    affiliation.icon.alt
  • Yeoh, Hui-Ling
    affiliation.icon.alt
  • Khattak, Adnan
    affiliation.icon.alt
  • Zimmer, Lisa
    affiliation.icon.alt
  • Blank, Christian U
    affiliation.icon.alt
  • Ramelyte, Egle
    affiliation.icon.alt
  • et al

Journal/Series Title

Journal/Series Title

Journal/Series Title

Volume

Volume

Volume
10

Number

Number

Number
7

Page range/Item number

Page range/Item number

Page range/Item number
e004668

Item Type

Item Type

Item Type
Journal Article

Dewey Decimal Classifikation

Dewey Decimal Classifikation

Dewey Decimal Classifikation

Keywords

Cancer Research, Pharmacology, Oncology, Molecular Medicine, Immunology, Immunology and Allergy

Language

Language

Language
English

Publication date

Publication date

Publication date
2022-07-01

Date available

Date available

Date available
2022-08-09

Publisher

Publisher

Publisher

ISSN or e-ISSN

ISSN or e-ISSN

ISSN or e-ISSN
2051-1426

OA Status

OA Status

OA Status
Gold

Free Access at

Free Access at

Free Access at
Pubmed ID

PubMed ID

PubMed ID

PubMed ID

Citations

Citation copied

Bhave, P., Ahmed, T., Lo, S. N., Shoushtari, A., Zaremba, A., Versluis, J. M., Mangana, J., Weichenthal, M., Si, L., Lesimple, T., Robert, C., Trojanello, C., Wicky, A., Heywood, R., Tran, L., Batty, K., Dimitriou, F., Stansfeld, A., Allayous, C., … et al. (2022). Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma. Journal for ImmunoTherapy of Cancer, 10, e004668. https://doi.org/10.1136/jitc-2022-004668

Gold Open Access
Loading...
Thumbnail Image

Files

Files

Files
Files available to download:1

Files

Files

Files
Files available to download:1
Loading...
Thumbnail Image